StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Core adjustment — Total restructuring charges by Quarter

Core adjustment — Total restructuring charges ($M) ($M)

QuarterlyAnnual

AstraZeneca Core adjustment — Total restructuring charges: -$100M in Q2 2026, down 576.2% from a year earlier.

Latest, Q2 2026
-100
Period ended Jun 30, 2026
Change on a year earlier
-576.2%
21 in Q2 2025
History
22 quarters
Since Q4 2020
Sources
22
Documents cited below

Where the Q2 2026 figure comes from

“|| Operating profit | | 3,164 | | | 100 | | | 1,546 | | 348 | | 5,158 | 12 | 10”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Reported-to-Core Reconciliation.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCore adjustment — Total restructuring charges ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026-100-576.2%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026-60-50.8%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025-57-43.0%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025-79-88.8%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202521-113.6%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025-122-37.4%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024-100-13.0%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024-705+468.5%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024-154+25.2%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024-195+85.7%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023-115-53.4%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023-124-23.0%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023-123-47.4%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023-105+40.0%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022-247-66.4%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022-161–Form 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Core adjustment — Total restructuring charges ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/adj-restructuring-total

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.